Claims for Patent: 8,840,887

Summary for Patent: 8,840,887

Title:	Antibodies
Abstract:	The present invention relates to the use of VEGF antagonists and a novel anti-.alpha.5.beta.1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-.alpha.5.beta.1 antibodies and methods of making and using them.
Inventor(s):	Liang; Wei-Ching (Foster City, CA), Plowman; Gregory D. (San Carlos, CA), Wu; Yan (Foster City, CA), Ye; Weilan (Foster City, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	13/112,839
Patent Claims:	1. A method for treating solid tumor in a subject comprising administering a VEGF antagonist and a humanized anti-.alpha.5.beta.1 antibody, wherein the humanized anti-.alpha.5.beta.1 antibody comprises a light chain variable domain having a sequence set forth in any one of SEQ ID NOS:1, 2, 3, or 4 and a heavy chain variable domain having a sequence set forth in any one of SEQ ID NOS:5, 6, 7, 8, or 9. 2. The method of claim 1, wherein the subject is further administered a therapeutic agent selected from the group consisting of an anti-neoplastic agent, a chemotherapeutic agent, a growth inhibitory agent and a cytotoxic agent. 3. The method of claim 1, wherein the VEGF antagonist can be competitively inhibited from binding to human VEGF by bevacizumab. 4. The method according to claim 3, wherein the VEGF antagonist is bevacizumab. 5. The method of claim 1, wherein the anti-.alpha.5.beta.1 antibody does not bind alphaVbeta3 or alphaVbeta5 or alphaVbeta1. 6. The method of claim 1, wherein the anti-.alpha.5.beta.1 antibody comprises an Fc sequence of a human IgG. 7. The method of claim 6, wherein the human IgG is hIgG1 or hIgG4. 8. The method of claim 6, wherein the anti-.alpha.5.beta.1 antibody comprises an Fc sequence that lacks antibody dependent cellular cytotoxicity (ADCC) effector function. 9. The method of claim 8, wherein the Fc sequence comprises a D265A substitution. 10. The method of claim 1, wherein the anti-.alpha.5.beta.1 antibody is selected from the group consisting of a Fab, Fab', a F(ab)'.sub.2, single-chain Fv (scFv), an Fv fragment, a diabody and a linear antibody. 11. The method of claim 1, wherein the anti-.alpha.5.beta.1 antibody is a multi-specific antibody. 12. The method of claim 1, wherein the anti-.alpha.5.beta.1 antibody is conjugated to a therapeutic agent. 13. The method of claim 12, wherein the therapeutic agent is selected from the group consisting of a cytotoxic agent, a radioisotope and a chemotherapeutic agent. 14. The method of claim 1, wherein the anti-.alpha.5.beta.1 antibody is conjugated to a label. 15. The method of claim 14, wherein the label is selected from the group consisting of a radioisotope, fluorescent dye and enzyme. 16. The method of claim 1, wherein the humanized anti-.alpha.5.beta.1 antibody comprises a light chain variable domain having a sequence set forth in SEQ ID NO:1 and a heavy chain variable domain having a sequence set forth in SEQ ID NO:5. 17. The method of claim 1, wherein the humanized anti-.alpha.5.beta.1 antibody comprises a light chain variable domain having a sequence set forth in SEQ ID NO: 2 and a heavy chain variable domain having a sequence set forth in SEQ ID NO: 6. 18. The method of claim 1, wherein the humanized anti-.alpha.5.beta.1 antibody comprises a light chain variable domain having a sequence set forth in SEQ ID NO: 2 and a heavy chain variable domain having a sequence set forth in SEQ ID NO: 7. 19. The method of claim 1, wherein the humanized anti-.alpha.5.beta.1 antibody comprises a light chain variable domain having a sequence set forth in SEQ ID NO: 3 and a heavy chain variable domain having a sequence set forth in SEQ ID NO: 8. 20. The method of claim 1, wherein the humanized anti-.alpha.5.beta.1 antibody comprises a light chain variable domain having a sequence set forth in SEQ ID NO: 4 and a heavy chain variable domain having a sequence set forth in SEQ ID NO: 9.

Details for Patent 8,840,887

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2027-09-26